Cannara Biotech Inc. (TSX:LOVE)
Canada · Delayed Price · Currency is CAD 1.890
-0.030 (-1.56%)
Jul 20, 2026, 3:59 PM EST
Cannara Biotech Income Statement
Financials in millions CAD. Fiscal year is September - August.
Millions CAD. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
| 117.45 | 107.32 | 82.15 | 57.56 | 36 | 17.27 | |
Revenue Growth (YoY) | 14.66% | 30.64% | 42.71% | 59.91% | 108.48% | 723.43% |
Cost of Revenue | 67.36 | 60.1 | 51.96 | 36.49 | 21.85 | 8.53 |
Gross Profit | 50.09 | 47.22 | 30.19 | 27.53 | 17.49 | 10.54 |
Selling, General & Admin | 28.97 | 23.17 | 19.65 | 13.52 | 10.03 | 7.3 |
Depreciation & Amortization Expenses | 1.54 | 1.56 | 1.38 | 0.96 | 1.23 | 1.03 |
Research & Development | 1.22 | 0.71 | 1.12 | 1.03 | 1.26 | 1.91 |
Other Operating Expenses | 0.25 | -0.41 | -2.03 | 0.13 | 0.06 | 0.09 |
Total Operating Expenses | 31.98 | 25.03 | 20.11 | 15.65 | 12.57 | 10.33 |
Operating Income | 18.66 | 22.2 | 10.08 | 11.89 | 4.94 | 0.26 |
Interest Expense | -2.39 | -4.1 | -5.59 | -4.94 | -2.64 | -1.79 |
Total Non-Operating Income (Expense) | -2.39 | -4.1 | -5.59 | -4.94 | -2.64 | -1.79 |
Pretax Income | 16.27 | 18.1 | 4.48 | 6.95 | 2.31 | -1.53 |
Provision for Income Taxes | 5.42 | 5.02 | -1.95 | - | - | - |
Net Income | 10.86 | 13.08 | 6.44 | 6.95 | 2.31 | -1.53 |
Net Income to Common | 10.86 | 13.08 | 6.44 | 6.95 | 2.31 | -1.53 |
Net Income Growth | -30.02% | 103.09% | -7.30% | 201.26% | - | - |
Shares Outstanding (Basic) | 95 | 91 | 90 | 89 | 88 | 77 |
Shares Outstanding (Diluted) | 97 | 92 | 91 | 90 | 88 | 77 |
Shares Change (YoY) | 5.25% | 1.08% | 1.83% | 2.16% | 14.80% | 24.45% |
EPS (Basic) | 0.11 | 0.14 | 0.07 | 0.08 | 0.03 | -0.10 |
EPS (Diluted) | 0.11 | 0.14 | 0.07 | 0.08 | 0.03 | -0.10 |
EPS Growth | -35.29% | 100.00% | -12.50% | 166.67% | - | - |
Free Cash Flow | 5.69 | 13.65 | 3.21 | -3.97 | -21.55 | -33.17 |
Free Cash Flow Growth | -58.30% | 324.86% | - | - | - | - |
Free Cash Flow Per Share | 0.06 | 0.15 | 0.04 | -0.04 | -0.25 | -0.43 |
Gross Margin | 42.65% | 44.00% | 36.75% | 47.83% | 48.58% | 61.06% |
Operating Margin | 15.89% | 20.68% | 12.27% | 20.65% | 13.73% | 1.49% |
Profit Margin | 9.25% | 12.18% | 7.84% | 12.07% | 6.40% | -8.85% |
FCF Margin | 4.85% | 12.72% | 3.91% | -6.89% | -59.85% | -192.08% |
EBITDA | 25.41 | 28.88 | 16.43 | 16.83 | 8.86 | 3.28 |
EBITDA Margin | 21.64% | 26.91% | 20.00% | 29.24% | 24.62% | 19.02% |
EBIT | 18.66 | 22.2 | 10.08 | 11.89 | 4.94 | 0.26 |
EBIT Margin | 15.89% | 20.68% | 12.27% | 20.65% | 13.73% | 1.49% |
Effective Tax Rate | 33.28% | 27.74% | -43.59% | 0.00% | 0.00% | 0.00% |